Bioactive Products
A unique collection of 267 Inhibitor natural compounds | ||
Catalog No: | Bb221 | Inhibitors Compound Library Screening Details |
Size: | 1mg/well * 267 Compounds 2mg/well * 267 Compounds |
Cat. No. | Information |
CFN92150 | Isochamaejasmine Isochamaejasmine has inhibition of NF-kappaB activation, which could reverse the anti-apoptotic effect; it induces apoptosis in leukemia cells by inhibiting the activity of Bcl-2 family proteins, providing evidence for further studying the underlying anti-cancer mechanism of S. chamaejasme L. Isochamaejasmine shows antiplasmodial activity, with an IC(50) of 7.3+/-3.8 microM, but the selectivity was rather limited. |
CFN92167 | Danshenol A Danshenol A has strong aldose reductase (AR) inhibitory activity, has IC50 of 0.10 microM which is comparable to that of epalrestat in clinical use. Danshenol A also has antitumor activity in T-24, QGY, K562, Me180 and BIU87 cell lines, shows inhibited growth of K562 (IC50 = 0.53 μg/mL), T-24 (IC50 = 7.94 μg/mL), QGY (IC50 = 4.65 μg/mL) and Me180 (IC50 = 6.89 μg/mL) cell lines. |
CFN92174 | 1,2-Benzenedicarboxylic acid 1,2-Benzenedicarboxylic acid is one kind of allelochemical shows stronger allelopathic effect on itself than on wheat and pigeonpea. 1,2-Benzenedicarboxylic acid has antimicrobial activity, it shows anti-extended-spectrum beta-lactamases (ESBL) activity. |
CFN92187 | Sugiol Sugiol has antioxidant efficacy, it has significant scavenging activities of 1,1-diphenyl-2-picryl hydrazyl, nitric oxide, superoxide and hydroxyl free radicals. Sugiol's efficacy in inhibiting the inflammatory cytokines of IL-1beta and TNF-alpha could be attributed to a reduction of the ROS that leads to a decrease in the phosphorylation of MAPKs. |
CFN90498 | Cycloart-23-ene-3,25-diol Cycloart-23-ene-3,25-diol has anti-inflammatory activity, it has protective activity against streptozotocin induced toxicity. Cycloart-23-ene-3,25-diol treatment can decrease liver malondialdehyde but increase superoxidase dismutase and reduced glutathione. |